TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24953576
Drug: Glycerin suppository
Normalized name: Leader Pediatric Glycerin Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppository (1g) once a day from day‐2 to day‐14 of life
Study: 24953576
Drug: No suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: No suppository
Study: 21546099
Drug: Daily vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vardenafil 10mg
Study: 15991553
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with Novo‐Helisen Depot allergy vaccines for 3 years
Study: 12912694
Drug: Elective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective treatment (enucleation or eye-conserving radiotherapy)
Study: 6119096
Drug: bunitrolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: bunitrolol (10 mg)
Study: 26509682
Drug: Muscle-Energy Techniques
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle-Energy Techniques (MET) - 2 treatment sessions per week for 6 weeks
Study: 17183623
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of disease modifying antirheumatic drugs (DMARD; COMBI)
Study: 15215224
Drug: Imipenem/cilastatin (1000/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1000/500 mg) instilled
Study: 15215224
Drug: Tobramycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (200 mg) instilled
Study: 557329
Drug: Inhalation provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation provocation tests with formalin
Study: 30851499
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided erector spinae plane (ESP) block with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Study: 30851499
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided Quadratus Lumborum Block (QLB) with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Study: 26506582
Drug: Guanfacine Extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine Extended Release (GXR) 1-7 mg per day
Study: 22974284
Drug: Optimized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized formulation (CCT T8) with core tablet (C8) and mannitol, lag time of 6 hrs before immediate release of drug.
Study: 22974284
Drug: Optimized solid
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized solid dispersion (S9) used for formulating optimized core tablet formulation (C8).
Study: 21300933
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus CAPIRI (irinotecan 200 mg/m(2), capecitabine 800 mg/m(2) twice daily)
Study: 21300933
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus CAPOX (oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2) twice daily)
Study: 16989024
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream applied 5 or 7 days a week for six weeks
Study: 16989024
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream applied 5 times a week
Study: 16989024
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream applied daily
Study: 16989024
Drug: Surgical excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision (standard treatment)
Study: 12628884
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (MA) 160 mg (8 mL)
Study: 12628884
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution 8 mL)
Study: 8165613
Drug: Factor V
Normalized name: Factor V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor V deficiency and specific inhibitors of factor V
Study: 24656153
Drug: 10‐mg generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg generic formulation (test)
Study: 24656153
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation (reference)
Study: 20391081
Drug: 6.4% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate-electrolyte solution
Study: 20391081
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (8 ml x kg BM(‐1))
Study: 17922561
Drug: Naloxone (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (continuous infusion)
Study: 12706638
Drug: Reviparin-sodium (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin-sodium (low molecular weight heparin), administered twice daily.
Study: 1912675
Drug: First chemotherapy
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First chemotherapy (105 women)
Study: 1912675
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation therapy (64 women)
Study: 1912675
Drug: Self-evaluation by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-evaluation by 64 women one year after treatment
Study: 1912675
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (78 women)
Study: 6874413
Drug: Safflower seed
Normalized name: SAFFLOWER SEED
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower seed oil (60 ml/d)
Study: 10896014
Drug: Aspirin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (900 mg)
Study: 30831478
Drug: Personalized modular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized modular treatment based on cognitive-behavioral therapy
Study: 24158227
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (8-week treatment)
Study: 22999073
Drug: Abciximab treatment
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab treatment in group A (additional platelet inhibition)
Study: 22999073
Drug: Conventional anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulation with heparin in group C1 (control group)
Study: 22999073
Drug: Conventional anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulation with heparin in group C2 (control group)
Study: 20393175
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (infliximab + azathioprine)
Study: 12351526
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of GnRH agonist administration for 1 week after hCG injection
Study: 7423170
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate (220 mg, three daily doses)
Study: 23218813
Drug: Supplemental parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental parenteral nutrition (SPN)
Study: 28873109
Drug: Clindamycin cream
Normalized name: clindamycin Vaginal Cream
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin cream 0.3% once daily
Study: 28873109
Drug: Clindamycin cream
Normalized name: clindamycin Vaginal Cream
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin cream 1% once or twice daily
Study: 28873109
Drug: Clindamycin gel
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin gel 1% twice daily
Study: 27313086
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine group (six courses of alternating R-CHOP or R-DHAP followed by high-dose cytarabine-containing conditioning regimen and ASCT)
Study: 27313086
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine group
Study: 19616668
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day
Study: 19616668
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/day, up titrated to 10 mg/day
Study: 11401925
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (5 mg daily for 1 year)
Study: 9479360
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy with tularemia booster (TB) and anticoagulant treatment (fibrinolysin, pelentan, and aspirin)
Study: 9479360
Drug: TB inoculation
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB inoculation without anticoagulants (control group 2)
Study: 3604886
Drug: Bipolar noncapturing
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bipolar noncapturing conditioning stimuli (Sc) with pulse widths of 2 or 9 msec and strengths of twice diastolic threshold and 10 MA
Study: 3604886
Drug: Unipolar cathodal
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unipolar cathodal noncapturing conditioning stimuli (Sc) with pulse widths of 2 or 9 msec and strengths of twice diastolic threshold and 10 MA
Study: 29718968
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.3 g·kg‐1 body weight)
Study: 28473520
Drug: Monthly sanitary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly sanitary pads
Study: 25732222
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 125 ml ONS (2.4 kcal/ml)/d for 12 weeks
Study: 20978528
Drug: High-fat yogurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat yogurt supplement
Study: 20978528
Drug: Low-fat yogurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yogurt supplement
Study: 12965979
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with ACE inhibitors
Study: 12965979
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy without ACE inhibitors
Study: 2223358
Drug: Prolonged administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged administration of 1% isoflurane (5 patients)
Study: 21159081
Drug: Home-based management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based management of malaria + Seasonal intermittent preventive treatment (IPTc) with AS+AQ
Study: 21159081
Drug: Home-based management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based management of malaria + Seasonal intermittent preventive treatment (IPTc) with AS+AQ (only children who received all three courses of IPTc)
Study: 19809023
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (BLF) 100 mg/d
Study: 19809023
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (BLF) 100 mg/d plus Lactobacillus rhamnosus GG (LGG) 6 x 10(9) colony-forming units/d
Study: 7845753
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (65 mg/kg/day once daily, Group A, n = 25)
Study: 7845753
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime (10 mg/kg/day divided every 12 hours, Group B, n = 25)
Study: 7845753
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (Group A)
Study: 7845753
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime (Group B)
Study: 26257323
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy with standard prandial insulin boluses
Study: 26257323
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy with prandial boluses reduced by 25%
Study: 21859656
Drug: Soy drink
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy drink (240 cc)
Study: 19706088
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream applied once or twice daily under occlusion for 6 weeks
Study: 18257271
Drug: Migu tablet
Normalized name: Pseudomonas aeruginosa (schroeter, 1872) migula, 1900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migu tablet (MG)
Study: 2470310
Drug: Cisplatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, 80 mg/m2 alone (CDDP regimen)
Study: 2470310
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (MOB-P: vincristine 1 mg, methotrexate 10 mg/m2 d 1, 2, 3, bleomycin 10 mg/m2 d 1, 2, 3)
Study: 2470310
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (MOB-P)
Study: 31605797
Drug: Pemetrexed +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed + Gefitinib (P+G)
Study: 29844250
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Control Group C)
Study: 28802634
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration in RS group
Study: 28802634
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration in NS group
Study: 9349079
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous ephedrine 0.25 mg.kg‐1
Study: 9349079
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid preloading with Hartmann's solution 20 ml.kg‐1
Study: 8223792
Drug: Placebo (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (current therapy)
Study: 3707815
Drug: Acyclovir tablets
Normalized name: Acyclovir Tablets
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir tablets (2 X 200 mg)
Study: 3707815
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of acyclovir (400 mg in 500 ml of 5% dextrose solution over 4 h)
Study: 3707815
Drug: Sipping acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sipping acyclovir solution (same as infusion, sipped at 10.4 ml every 5 min for 4 h)
Study: 3707815
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of acyclovir (400 mg)
Study: 3707815
Drug: Sipping acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sipping acyclovir solution
Study: 29762363
Drug: DTaP-IPV-HB-PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRP-T vaccine (group 1)
Study: 17662090
Drug: L-Citrulline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Citrulline (3 g bid)
Study: 16380708
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg daily for 6 months)
Study: 12747281
Drug: Rofecoxib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 500 mg
Study: 8821514
Drug: Nifedipine extended
Normalized name: Nifedipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine extended release capsule (Aprical retard)
Study: 8821514
Drug: Standard retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard retard tablet
Study: 1483293
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (75 g) + pyridostigmine (120 mg)
Study: 1483293
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + pyridostigmine (120 mg)
Study: 1483293
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg) alone
Study: 2990708
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (cyclophosphamide, vincristine, semustine)
Study: 2990708
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (cyclophosphamide, vincristine, semustine)
Study: 2990708
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (cyclophosphamide, vincristine, semustine) in patients with extensive disease
Study: 2990708
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (cyclophosphamide, vincristine, semustine) in patients with extensive disease
Study: 29782217
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg every 2 weeks in patients with eosinophil count ≥300/mm³
Study: 22412837
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day for 14 days)
Study: 22412837
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/day for 4 days)
Study: 12647845
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of insulin lispro before the afternoon meal
Study: 26547499
Drug: Ledipasvir/Sofosbuvir (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir (once-daily dosage)
Study: 24556911
Drug: Intravenous L‐alanyl‐L‐glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L‐alanyl‐L‐glutamine dipeptide supplementation (0.5 g/kg body weight/day) for 5 days
Study: 21778673
Drug: Menatetrenone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (45 mg daily) and risedronate sodium (once weekly)
Study: 21778673
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and risedronate sodium (once weekly)
Study: 16400468
Drug: Gabexate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate (300 mg continuous intravenous infusion in 500 mL Ringer's solution at 111 mL/h for 4.5 hours)
Study: 11268223
Drug: Garlic preparations
Normalized name: garlic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic preparations
Study: 8335855
Drug: Heated moisturized
Normalized name: HEAT/MOISTURE EXCHANGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated moisturized air (delivered at 40 L/min and 43 degrees C)
Study: 31190822
Drug: 20-Hz rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-Hz rTMS treatment for 4 weeks
Study: 21461716
Drug: Balneotherapy (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (21 patients) - 2 thermomineral water baths daily for 2 weeks
Study: 21461716
Drug: Control (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (24 patients) - continued medical treatment and routine daily life
Study: 16626957
Drug: Soy with
Normalized name: pediatric nutrition, soy with iron, lactose free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy with trace isoflavones (<4 mg)
Study: 16626957
Drug: Soy with
Normalized name: pediatric nutrition, soy with iron, lactose free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy with 107 mg of total aglycone units of isoflavones
Study: 17516694
Drug: Oxybutynin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin XL 10 mg/day
Study: 17516694
Drug: Tolterodine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine IR 4 mg/day
Study: 11068350
Drug: Orthodox medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodox medicine
Study: 11068350
Drug: Complementary medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary medicine users
Study: 11068350
Drug: Non-complementary medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-complementary medicine users
Study: 8943602
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol and sufentanil (group A)
Study: 6384848
Drug: butoconazole nitrate
Normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: butoconazole nitrate cream 2%
Study: 6384848
Drug: clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: clotrimazole vaginal tablets 200 mg/day
Study: 25475929
Drug: Teneligliptin 20mg
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20mg plus metformin
Study: 19782008
Drug: Stumvoll's early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stumvoll's early insulin secretion index in CF-NGT patients
Study: 19782008
Drug: Insulin secretion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin secretion rate (ISR) in CF-NGT and CFRD groups